- PRPO shares jumped 172pc on Monday.
- Amazon (AMZN) offered the diagnostic company’s COVID-19 test on its platform.
- Without resistance, Precipio could rise to $7 a share.
After exploding 172pc on Monday, May 3, Precipio is riding up more than 30% in Tuesday’s premarket.
The catalyst for the vertical lift-off? Amazon (AMZN) launched PRPO’s rapid COVID-19 antibody test on the world’s biggest e-commerce website. The 20-minute test can only be purchased by medical practitioners and institutions but can be delivered in two days using Amazon’s logistics system.
The test is being sold under the trade name MidaSpot and is produced by US-based Nirmidas Biotech.
PRPO price forecast: Where to from here?
After Monday’s blast, PRPO shares easily eclipsed the February 9 local high of $4.24 and ended the day at $4.95.
Important to traders will be the fact that yesterday’s close coincides perfectly with the highs of July 31 and August 4, 2020, the first and third trading session after PRPO’s last crazy spike – which hit $8 on July 30, only to crater below $5 in the subsequent days and eventually trade down to $2 in the next nine months.
Will Monday’s euphoria once again quickly dim?
It is hard to say. With shares trading north of $5.70 in the premarket, and every daily moving average left in the dust, the next level up that bulls will aim for is $7, the close from July 30, 2020.
If this is surpassed, traders will target the high of last summer at $8.
If shares instead crater lower as happened in the previous hyper run-up, then bears will target the resistance-turned-support just under $4.
PRPO 1-day chart
At the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
This article is for information purposes only. The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice. It is important to perform your own research before making any investment and take independent advice from a registered investment advisor.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to accuracy, completeness, or the suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. The author will not be held responsible for information that is found at the end of links posted on this page.
Errors and omissions excepted.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD trades weak below 1.0800 amid Good Friday lull, ahead of US PCE
EUR/USD remains depressed below 1.0800 after soft French inflation data, amid minimal volatility and thin liquidity on Good Friday. The pair keenly awaits the US PCE inflation data and Fed Chair Powell's speech for fresh hints on next week's price action.
GBP/USD holds steady above 1.2600 as markets stay calm on Good Friday
GBP/USD trades sideways above 1.2600 amid a typical Good Friday trading lull. A broadly firmer US Dollar could keep any upside attempts limited in the pair ahead of the US PCE inflation data and Fed Chair Powell's appearance.
Gold price sits at all-time highs above $2,230, US PCE eyed
Gold price hit all-time highs at $2,236 on Thursday to finish Q1 2024 with a bang. Most major world markets, including the US are closed due to Holy Friday, leaving volatility around Gold price highly subdued. US PCE inflation and Powell are awaited.
Jito price could hit $6 as JTO coils up inside this bullish pattern
Jito (JTO) price has been on an uptrend since forming a local bottom in early January. Since then, JTO has revisited the key swing point formed in early December, suggesting the bulls’ intention to move higher.
Key events in developed markets next week
Next week, the main focus will be inflation and the labour market in the Eurozone. We expect services inflation to be impacted by the easter effect, while the unemployment rate to be unchanged.